Friday, October 18, 2019

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Utilizing Artificial Intelligence, Smart Tumor Profiling to Augment Clinical Outcomes


Predictive Oncology (NASDAQ: POAI), a developer of highly adaptable assessment methods for cancer patients to help guide personalized treatments, employs its proprietary smart tumor profiling and artificial intelligence (“AI”) platform to predict tumor drug response and improve clinical outcomes for cancer patients. An article discussing the company’s activities further reads, “Last year, POAI, then known as Precision Therapeutics, formed TumorGenesis to focus on innovative ways to create improved patient-derived (PDx) tumor models. Currently, TumorGenesis is working on developing new techniques for growing tumors in the lab to generate more relevant models of the tumors that can be used to test drugs for personalized therapy or aid in development of new medications. . . .The approach is designed to grow tumors in the lab by providing an environment that closely mimics the human body through the use of chemistry, biology, mechanics and cell nutrients. In addition to this exclusive technology being quicker and more affordable than existing PDx animal models, researchers anticipate that the approach will better replicate the characteristics of tumors. Initially, the company plans to develop PDx models for multiple myeloma, triple-negative breast cancer and ovarian cancer, but Predictive is expecting the technology to ultimately benefit oncologists who are investigating other cancer areas as well, including liver, pancreatic, lung and colon.”

To view the full article, visit http://ibn.fm/pALP6

About Predictive Oncology Inc.

Predictive Oncology operates in two business areas: first, applying artificial intelligence to personalized medicine and drug discovery to provide personalized medicine solutions for patients and clinicians as well as clients in the pharmaceutical, diagnostic and biotech industries; and second, production of the FDA-approved STREAMWAY(R) System for automated, direct-to-drain medical fluid disposal. For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php


No comments: